CHEK1 (Ab-280) Antibody

What is the biological significance of CHEK1 Ser280 phosphorylation?

Phosphorylation of CHEK1 at Serine 280 plays a critical role in regulating its subcellular localization and activity. Research demonstrates that this phosphorylation is essential for nuclear retention of CHEK1, particularly in response to serum stimulation . P90 RSK facilitates this nuclear retention through CHEK1-Ser-280 phosphorylation, which differs from the previously assumed exclusive role of Akt/PKB in this process . Additionally, CHEK1-Ser-280 phosphorylation is elevated after UV irradiation in a p90 RSK-dependent manner, accelerating the CHEK1 activation process (through subsequent Ser-345 and Ser-296 phosphorylation) . This phosphorylation event represents a crucial regulatory mechanism in the DNA damage response pathway.

How does CHEK1 function in cell cycle regulation and DNA damage response?

CHEK1 is required for checkpoint-mediated cell cycle arrest in response to DNA damage or the presence of unreplicated DNA. It may also negatively regulate cell cycle progression during unperturbed cell cycles . Mechanistically, CHEK1 recognizes the substrate consensus sequence [R-X-X-S/T] and phosphorylates several cell cycle regulators including CDC25A, CDC25B, and CDC25C . These phosphorylation events create binding sites for 14-3-3 proteins, which inhibit CDC25A and CDC25C, leading to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocking cell cycle progression . CHEK1 also phosphorylates RAD51, which may enhance its association with DNA damage sites, demonstrating CHEK1's multifaceted role in maintaining genomic integrity.

Experimental Applications and Methodology

To validate antibody specificity, implement the following methodological approaches:

• Peptide competition assay: Pre-incubate the antibody with phosphopeptide pS280 corresponding to Ser-280-phosphorylated CHEK1. As demonstrated in published research, this should impair immunoreactivity, while non-phosphorylated peptide S280 and phosphopeptides for other sites within CHEK1 should not affect binding .

• Genetic validation: Use CHEK1 knockout cells or siRNA-mediated depletion of endogenous CHEK1 to confirm signal specificity.

• Phosphatase treatment: Treat cell lysates with lambda phosphatase to remove phosphate groups and confirm loss of signal with the phospho-specific antibody.

• Mutant expression: Compare detection in cells expressing wild-type CHEK1 versus non-phosphorylatable mutant (S280A) and phosphomimetic mutant (S280E) . This approach has been successfully used to demonstrate that nuclear accumulation of CHEK1 is mediated through Ser-280 phosphorylation.

What are the optimal sample preparation methods for detecting phospho-CHEK1 (Ser280)?

For optimal detection of phosphorylated CHEK1 at Ser280:

• Lysis buffer composition: Use phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, with 150mM NaCl, including phosphatase inhibitors (sodium fluoride, sodium orthovanadate, and β-glycerophosphate) .

• Stimulation conditions: For studying serum-induced phosphorylation, serum-starve cells overnight, then stimulate with 10% serum for 10 minutes before lysis .

• Subcellular fractionation: Since phospho-CHEK1 (Ser280) localizes predominantly to the nucleus after stimulation, consider separating nuclear and cytoplasmic fractions for more precise analysis .

• Sample preservation: Store lysates at -80°C with 50% glycerol to prevent repeated freeze-thaw cycles which may degrade phosphorylated proteins .

• Protein loading: Load 20-40 μg of total protein for Western blot analysis to detect endogenous levels of phospho-CHEK1 (Ser280).

What controls should be included when studying CHEK1 phosphorylation dynamics?

Include the following controls to ensure rigorous experimental design:

• Total CHEK1 detection: Always probe for total CHEK1 in parallel to assess changes in phosphorylation versus total protein expression.

• Pathway activation markers: Include markers of the PI3K/Akt and MAPK/RSK pathways (e.g., phospho-Akt, phospho-ERK, phospho-RSK) since both Akt and p90 RSK can phosphorylate CHEK1 at Ser280 .

• Cell cycle phase controls: Since CHEK1 function is cell cycle-dependent, consider synchronizing cells or including cell cycle phase markers (e.g., cyclin B1, phospho-histone H3).

• Kinase inhibitors: Use Akt inhibitors (e.g., MK2206) or RSK inhibitors (e.g., BI-D1870) to validate kinase-specific phosphorylation events .

• DNA damage controls: When studying CHEK1 in response to genotoxic stress, include markers of DNA damage (e.g., γH2AX) and checkpoint activation (e.g., phospho-CHEK1-Ser345).

How does phosphorylation at Ser280 relate to other CHEK1 phosphorylation sites during DNA damage response?

The relationship between various CHEK1 phosphorylation sites reveals a complex regulatory network:

• Temporal dynamics: Ser280 phosphorylation occurs rapidly after serum stimulation or UV irradiation . This appears to be upstream of the canonical activation sites Ser345 and Ser296, as Ser280 phosphorylation accelerates the Ser345 and Ser296 phosphorylation process after UV irradiation .

• Functional consequences: While ATR-mediated phosphorylation of Ser345 is required for CHEK1 activation in response to DNA damage, Ser280 phosphorylation by RSK or Akt plays a distinct role in regulating nuclear retention and possibly modulating CHEK1 activity .

• Inhibitory versus activating phosphorylation: Akt-mediated phosphorylation of Ser280 has been suggested to prevent CHEK1 activation, whereas RSK-mediated phosphorylation of the same site after UV irradiation accelerates CHEK1 activation . This apparent contradiction suggests context-dependent outcomes depending on the cellular state and signaling environment.

• Cross-regulation: Research should examine whether Ser280 phosphorylation affects subsequent phosphorylation events through conformational changes or protein-protein interactions.

• Methodological approach: To study these relationships, researchers should employ phospho-specific antibodies against multiple sites (Ser280, Ser345, Ser296) in time-course experiments with various stimuli.

What is the role of CHEK1 and its phosphorylation at Ser280 in cancer biology?

CHEK1 has significant implications in cancer biology with its phosphorylation state being particularly relevant:

• Expression patterns: Meta-analysis has shown that CHEK1 is highly expressed in multiple cancers and correlates with poor prognostic features including low differentiation (OR=3.94, 95% CI: 2.73-5.67), advanced stage (OR=3.20, 95% CI: 2.30-4.44), vascular infiltration (OR=3.24, 95% CI: 2.18-4.82), and lymph node metastasis (OR=3.55, 95% CI: 2.62-4.82) .

• Immune infiltration: CHEK1 expression significantly correlates with immune cell infiltration in various cancers, including B cells, CD4+ T cells, CD8+ T cells, dendritic cells, macrophages, and neutrophils across multiple cancer types . This suggests a potential immunomodulatory role for CHEK1.

• Therapeutic targeting: Understanding the regulation of CHEK1 through Ser280 phosphorylation may inform therapeutic strategies. Since Akt-mediated phosphorylation may prevent CHEK1 activation , combining CHEK1 inhibitors with PI3K/Akt pathway inhibitors could have synergistic effects in certain cancers.

• Biomarker potential: Phospho-CHEK1 (Ser280) could serve as a biomarker for activated Akt or RSK signaling in tumors, potentially identifying patients who might benefit from targeted therapies.

• Research methodology: To investigate this, researchers should employ tissue microarrays with phospho-specific antibodies, correlating expression with clinical outcomes and molecular features of tumors.

What are common issues when detecting phospho-CHEK1 (Ser280) and how can they be resolved?

Researchers may encounter several challenges when detecting phospho-CHEK1 (Ser280):

• Weak signal intensity:

  • Problem: Insufficient phosphorylation or antibody detection.

  • Solution: Optimize stimulation conditions (e.g., serum concentration, time course); use more concentrated antibody; employ signal amplification systems; ensure phosphatase inhibitors are fresh and active in lysis buffers.

• High background:

  • Problem: Non-specific antibody binding.

  • Solution: Increase blocking time/concentration; optimize antibody dilution; use different blocking agents (BSA vs. milk); include additional washing steps; consider using a different secondary antibody.

• Multiple bands:

  • Problem: Non-specific binding or CHEK1 isoforms/degradation products.

  • Solution: Validate with peptide competition assay ; use gradient gels for better separation; include positive controls (e.g., serum-stimulated cells).

• Inconsistent results:

  • Problem: Variable phosphorylation status or sample handling.

  • Solution: Standardize cell culture conditions; control cell density and passage number; process all samples simultaneously; include internal controls for normalization.

• Loss of phosphorylation during processing:

  • Problem: Phosphatase activity during sample preparation.

  • Solution: Keep samples cold; use fresh phosphatase inhibitors; minimize processing time; consider using phosphatase-resistant lysis buffers.

How can I optimize immunofluorescence detection of phospho-CHEK1 (Ser280)?

For optimal immunofluorescence detection:

• Fixation method: Use 4% paraformaldehyde for 15 minutes at room temperature to preserve phosphoepitopes. Avoid methanol fixation which can remove phosphate groups.

• Permeabilization: Optimize detergent concentration (0.1-0.5% Triton X-100) and time (5-15 minutes) to ensure adequate antibody access while preserving cellular structures.

• Antigen retrieval: If detecting phospho-CHEK1 in fixed tissues, consider citrate buffer (pH 6.0) or EDTA buffer (pH 8.0) for antigen retrieval.

• Signal amplification: For weak signals, employ tyramide signal amplification or use high-sensitivity detection systems.

• Controls: Include cells treated with phosphatase, cells expressing CHEK1 S280A mutant, and stimulated versus unstimulated cells as controls .

• Counterstaining: Use DAPI for nuclear staining to verify nuclear localization of phospho-CHEK1 (Ser280) following stimulation .

• Confocal microscopy: Employ confocal microscopy for better resolution of subcellular localization, particularly when examining nuclear versus cytoplasmic distribution.

How can phospho-CHEK1 (Ser280) antibodies be used to study cancer therapeutic resistance?

Phospho-CHEK1 (Ser280) antibodies can be valuable tools in studying therapeutic resistance:

• Treatment monitoring: Measure changes in CHEK1-Ser280 phosphorylation before and after treatment with chemotherapeutics or targeted therapies to identify adaptive signaling responses.

• Patient stratification: Analyze tumor biopsies for baseline phospho-CHEK1 (Ser280) levels to potentially identify patients likely to respond to certain therapies, particularly those targeting the DNA damage response or PI3K/Akt pathway.

• Resistance mechanisms: Compare phospho-CHEK1 (Ser280) levels between therapy-sensitive and resistant cell lines or patient samples to determine if altered CHEK1 regulation contributes to resistance.

• Combination therapy rationale: If increased phospho-CHEK1 (Ser280) is observed in resistant cells, this could provide rationale for combining DNA-damaging agents with inhibitors of the kinases responsible for this phosphorylation (Akt or RSK inhibitors).

• Methodology: Use immunohistochemistry on tissue microarrays from responders versus non-responders; perform Western blot analysis on patient-derived xenografts treated with various regimens; employ phospho-flow cytometry for single-cell analysis of heterogeneous tumor samples.

What experimental approaches can be used to study the interplay between CHEK1 and immune cells in the tumor microenvironment?

Given the significant correlation between CHEK1 expression and immune infiltration in various cancers , several experimental approaches can elucidate this relationship:

• Co-culture experiments: Design co-culture systems with cancer cells and various immune cell types (T cells, B cells, macrophages) to assess how CHEK1 activation or inhibition in cancer cells affects immune cell function and migration.

• Multiplexed immunofluorescence: Use phospho-CHEK1 (Ser280) antibody alongside immune cell markers in patient samples to analyze spatial relationships between CHEK1-activated cancer cells and infiltrating immune cells.

• Conditional knockdown models: Generate cancer cell lines with inducible CHEK1 knockdown or expression of phospho-mutants (S280A, S280E) and assess changes in cytokine production, immune checkpoint molecule expression, and immune cell recruitment in vivo.

• Signaling pathway analysis: Investigate whether CHEK1 activation modulates immunomodulatory pathways by analyzing changes in NFκB, STAT signaling, or interferon response gene expression following manipulation of CHEK1 or its phosphorylation state.

• Therapeutic implications: Test combinations of CHEK1 inhibitors with immunotherapies in preclinical models, using phospho-CHEK1 (Ser280) as a biomarker to track pathway modulation.

• Single-cell analysis: Apply single-cell RNA sequencing and phospho-proteomics to tumor samples to correlate CHEK1 activity with immune phenotypes at high resolution.